CROMA Australia Pty Ltd

Regulatory activities for this sponsor.

3 result(s) found, displaying 1 to 3

AusPAR: Letybo

14 November 2023

Australian Public Assessment Report (AusPAR)

Letybo (letibotulinumtoxinA) has been approved for temporary improvement in the appearance of glabellar frown lines in adults.
Letybo

7 December 2022

Prescription medicine decision summary

TGA decision: Letybo (letibotulinumtoxinA) is approved to treat the appearance of moderate to severe glabellar frown lines in adults.
LETYBO (CROMA Australia Pty Ltd)

23 November 2022

Prescription medicine registration

Active ingredients: letibotulinumtoxinA.